|
US3133858A
(en)
*
|
1954-03-24 |
1964-05-19 |
Abbott Lab |
Stable thiobarbituric acid solution
|
|
CH527207A
(de)
|
1968-05-08 |
1972-08-31 |
Ceskoslovenska Akademie Ved |
Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
|
|
DE2105468A1
(en)
|
1970-04-23 |
1971-11-18 |
Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen |
1-glycosyl-5-aza-cytosines prepn
|
|
US5157120A
(en)
|
1980-09-16 |
1992-10-20 |
Syntex (U.S.A.) Inc. |
Guanine derivatives
|
|
US4855304A
(en)
|
1985-01-10 |
1989-08-08 |
Repligen Corporation |
Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
|
|
JPS61176523A
(ja)
|
1985-01-30 |
1986-08-08 |
Teruhiko Beppu |
制癌剤
|
|
GB8612826D0
(en)
|
1986-05-27 |
1986-07-02 |
Boots Co Plc |
Insecticidal compositions
|
|
DE3712786A1
(de)
|
1987-04-15 |
1988-11-03 |
Merck Patent Gmbh |
Verfahren und mittel zur bestimmung von nucleinsaeuren
|
|
CS269077B1
(cs)
|
1987-10-01 |
1990-04-11 |
Piskala Alois |
Způsob přípravy 5-azacytosinů
|
|
US5736531A
(en)
|
1987-10-28 |
1998-04-07 |
Pro-Neuron, Inc. |
Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
|
|
US5968914A
(en)
|
1987-10-28 |
1999-10-19 |
Pro-Neuron, Inc. |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
|
US4904770A
(en)
|
1988-03-24 |
1990-02-27 |
Bristol-Myers Company |
Production of 2',3'-dideoxy-2',3'-didehydronucleosides
|
|
US5324831A
(en)
|
1988-04-06 |
1994-06-28 |
The United States Of America As Represented By The Secretary Of Health And Human Services |
Phosphoramidite reagent for chemical synthesis of modified DNA
|
|
PT93772A
(pt)
|
1989-04-17 |
1991-01-08 |
Searle & Co |
Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
|
|
ZA923641B
(en)
|
1991-05-21 |
1993-02-24 |
Iaf Biochem Int |
Processes for the diastereoselective synthesis of nucleosides
|
|
WO1993001202A1
(en)
|
1991-07-05 |
1993-01-21 |
Pro-Neuron, Inc. |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
|
IL103311A0
(en)
|
1991-10-07 |
1993-03-15 |
Univ Johns Hopkins |
Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
|
|
JPH05219974A
(ja)
|
1992-02-13 |
1993-08-31 |
Mitsui Petrochem Ind Ltd |
トロパンアルカロイドの製造方法
|
|
JPH05246891A
(ja)
*
|
1992-03-09 |
1993-09-24 |
Kobayashi Seiyaku Kogyo Kk |
安定な抗膵炎用注射液
|
|
US5607691A
(en)
|
1992-06-12 |
1997-03-04 |
Affymax Technologies N.V. |
Compositions and methods for enhanced drug delivery
|
|
AU6081294A
(en)
|
1993-05-14 |
1994-12-12 |
Pro-Neuron, Inc. |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
|
GB9311252D0
(en)
|
1993-06-01 |
1993-07-21 |
Hafslund Nycomed As |
Cell growth regualtors
|
|
AU1061395A
(en)
|
1993-11-30 |
1995-06-19 |
Mcgill University |
Inhibition of dna methyltransferase
|
|
US6432924B1
(en)
|
1993-12-26 |
2002-08-13 |
East Carolina University |
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
|
|
US5856090A
(en)
|
1994-09-09 |
1999-01-05 |
The Scripps Research Institute |
DNA-methylase linking reaction
|
|
US20030104576A1
(en)
|
1994-10-07 |
2003-06-05 |
Jonathan W. Nyce |
Dna construct, composition, formulations & methods for making the construct & for modulating expression
|
|
CA2221411A1
(en)
|
1995-05-19 |
1996-11-21 |
Phytera, Inc. |
Manipulation of plant cell and tissue cultures
|
|
EP0852463B1
(en)
|
1995-06-06 |
2008-09-03 |
Case Western Reserve University |
Myogenic differentiation of human mesenchymal stem cells
|
|
US6136791A
(en)
|
1995-12-22 |
2000-10-24 |
East Carolina University |
Agent and method for treating disorders associated with cytidine deaminase or deoxycytidine deaminase overexpression
|
|
CZ120699A3
(cs)
|
1996-10-16 |
1999-09-15 |
Icn Pharmaceuticals, Inc. |
Monocyklická L-nukleosidová analoga a jejich využití
|
|
US6423692B2
(en)
|
1997-04-24 |
2002-07-23 |
Dana-Farber Cancer Institute, Inc. |
Method of enhancing the effectiveness of DCK phosphorylated molecules
|
|
US6153383A
(en)
|
1997-12-09 |
2000-11-28 |
Verdine; Gregory L. |
Synthetic transcriptional modulators and uses thereof
|
|
JP4768121B2
(ja)
|
1998-02-05 |
2011-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Ｍａｇｅファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用
|
|
WO2000023112A1
(en)
|
1998-10-19 |
2000-04-27 |
Methylgene, Inc. |
Modulation of gene expression by combination therapy
|
|
EP3553085A1
(en)
|
1998-12-23 |
2019-10-16 |
Pfizer Inc |
Human momoclonal antibodies to ctla-4
|
|
WO2000040269A2
(en)
|
1999-01-05 |
2000-07-13 |
Lee Clarence C |
Pharmaceutical compositions for treatment of diseased tissues
|
|
WO2000062075A1
(en)
|
1999-04-13 |
2000-10-19 |
Rutgers, The State University Of New Jersey |
Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity
|
|
US6599912B1
(en)
|
1999-06-03 |
2003-07-29 |
Jessie L. -S. Au |
Methods and compositions for modulating cell proliferation and cell death
|
|
DE19935303A1
(de)
|
1999-07-28 |
2001-02-08 |
Aventis Pharma Gmbh |
Oligonukleotide zur Inhibierung der Expression von humanem eg5
|
|
DK1212422T3
(da)
|
1999-08-24 |
2007-07-02 |
Medarex Inc |
Humane CTLA-4-antistoffer og anvendelserne deraf
|
|
JP2001163776A
(ja)
*
|
1999-09-30 |
2001-06-19 |
Nisshin Oil Mills Ltd:The |
安定化された液剤
|
|
WO2001029235A2
(en)
|
1999-10-18 |
2001-04-26 |
Emory University |
Tms1 compositions and methods of use
|
|
AU2001247444A1
(en)
|
2000-03-15 |
2001-09-24 |
University Of Massachusetts |
Erbeta-mediated gene expression
|
|
ATE461453T1
(de)
|
2000-09-08 |
2010-04-15 |
Seoul Nat Univ Ind Foundation |
Nukleinsäuresequenz und protein, das eine rolle bei der zellulären alterung spielt
|
|
JP2004536026A
(ja)
*
|
2000-11-28 |
2004-12-02 |
トランスフォーム ファーマシューティカルズ，インコーポレーティッド． |
パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
|
|
WO2002053138A2
(en)
|
2001-01-02 |
2002-07-11 |
Elisabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
|
DZ3487A1
(fr)
|
2001-01-22 |
2002-07-25 |
Merck Sharp & Dohme |
Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
|
|
JP2002223753A
(ja)
|
2001-01-30 |
2002-08-13 |
Hitachi Ltd |
薬物応答解析用オリゴヌクレオチドアレイ
|
|
CA2436340A1
(en)
|
2001-02-05 |
2002-10-03 |
Innoventus Project Ab |
Histidine-rich glycoprotein
|
|
US6613753B2
(en)
|
2001-02-21 |
2003-09-02 |
Supergen, Inc. |
Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
|
|
AU2002252183A1
(en)
|
2001-03-06 |
2002-09-19 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
|
|
US20060194275A1
(en)
|
2001-04-13 |
2006-08-31 |
Incyte Corporation |
Transporter and ion channels
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
EP1383504A1
(en)
|
2001-04-26 |
2004-01-28 |
Control Delivery Systems, Inc. |
Sustained release drug delivery system containing codrugs
|
|
US20030148973A1
(en)
|
2001-05-23 |
2003-08-07 |
Peter Emtage |
MAGE-A1 peptides for treating or preventing cancer
|
|
JP2004536596A
(ja)
|
2001-06-08 |
2004-12-09 |
ユー．エス． ジェノミクス， インコーポレイテッド |
メチル化状態に基づいて核酸を分析するための方法および生成物
|
|
JP2002370939A
(ja)
|
2001-06-12 |
2002-12-24 |
Taisho Pharmaceut Co Ltd |
育毛剤
|
|
US20030045497A1
(en)
|
2001-07-27 |
2003-03-06 |
Geneinvent Bbl Ab |
Methylation resistant vectors
|
|
SE0102627L
(sv)
|
2001-07-27 |
2002-11-19 |
Geneinvent Bbl Ab |
Vektorer motståndskraftiga mot metylering
|
|
WO2003012085A1
(en)
|
2001-07-30 |
2003-02-13 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Antigen presenting cells, method for their preparation and their use for cancer vaccines
|
|
PT2177223E
(pt)
|
2001-09-05 |
2012-05-23 |
Chemgenex Pharmaceuticals Ltd |
Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, envolvendo a homoharringtonina isoladamente ou em combinação com outros agentes
|
|
US20030158598A1
(en)
|
2001-09-17 |
2003-08-21 |
Control Delivery Systems, Inc. |
System for sustained-release delivery of anti-inflammatory agents from a coated medical device
|
|
IN2014DN10834A
(enExample)
|
2001-09-17 |
2015-09-04 |
Psivida Inc |
|
|
CA2461227C
(en)
|
2001-09-24 |
2012-05-15 |
Jessie L.-S Au |
Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
|
|
AU2002342004A1
(en)
|
2001-10-05 |
2003-04-22 |
Case Western Reserve University |
Methods and compositions for detecting colon cancers
|
|
EP1452592A4
(en)
|
2001-11-08 |
2006-02-15 |
Japan Science & Tech Agency |
TRANSPOSONGENE FROM RICE
|
|
WO2003043631A2
(en)
|
2001-11-23 |
2003-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for identification of tumor targeting enzymes
|
|
DE60234115D1
(de)
|
2001-11-29 |
2009-12-03 |
Dandrit Biotech As |
Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
|
|
WO2003046190A1
(de)
|
2001-11-30 |
2003-06-05 |
Medigene Aktiengesellschaft |
Optimierte herstellung von viralen, von parvoviren abgeleiteten vektoren in verpackungs- und produktionszellen durch hsv-infektion oder behandlung mit inhibitoren der dna-methylierung
|
|
GB0201498D0
(en)
|
2002-01-23 |
2002-03-13 |
Biotech Res Ventures Pte Ltd |
Materials and methods for treating cancer
|
|
US20030147813A1
(en)
|
2002-02-07 |
2003-08-07 |
John Lyons |
Method for treating chronic myelogenous leukemia
|
|
US6998391B2
(en)
|
2002-02-07 |
2006-02-14 |
Supergen.Inc. |
Method for treating diseases associated with abnormal kinase activity
|
|
WO2003076660A1
(en)
|
2002-03-13 |
2003-09-18 |
F.Hoffmann-La Roche Ag |
Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
|
|
JP2003310293A
(ja)
|
2002-04-26 |
2003-11-05 |
Mitsui Chemicals Inc |
ヌクレオシド化合物の製造法
|
|
BR122019027966B8
(pt)
|
2002-05-02 |
2021-07-27 |
Wyeth Corp |
conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
|
|
US6982253B2
(en)
|
2002-06-05 |
2006-01-03 |
Supergen, Inc. |
Liquid formulation of decitabine and use of the same
|
|
AU2003251483A1
(en)
|
2002-06-05 |
2003-12-22 |
Case Western Reserve University |
Methods and compositions for detecting cancers
|
|
EP1556010A4
(en)
|
2002-10-31 |
2007-12-05 |
Supergen Inc |
PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
|
|
US20050037992A1
(en)
|
2003-07-22 |
2005-02-17 |
John Lyons |
Composition and method for treating neurological disorders
|
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
|
WO2005033278A2
(en)
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
|
US7846436B2
(en)
|
2003-11-28 |
2010-12-07 |
Chemgenes Corporation |
Oligonucleotides and related compounds
|
|
US20050266012A1
(en)
|
2004-05-26 |
2005-12-01 |
Jean-Marie Andrieu |
Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
|
|
US20060014949A1
(en)
|
2004-07-13 |
2006-01-19 |
Supergen Inc. |
Compositions and formulations of decitabine polymorphs and methods of use thereof
|
|
US20060063735A1
(en)
|
2004-09-17 |
2006-03-23 |
Supergen, Inc. |
Salts of 5-azacytidine
|
|
US20060069060A1
(en)
|
2004-09-27 |
2006-03-30 |
Sanjeev Redkar |
Salts of decitabine
|
|
CA2586844A1
(en)
|
2004-11-04 |
2006-05-11 |
Pfizer Products Inc. |
Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
|
|
US20060128653A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
|
US20060128654A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
|
US20060159694A1
(en)
|
2004-12-29 |
2006-07-20 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in compositions for various types of cancers
|
|
US7250416B2
(en)
|
2005-03-11 |
2007-07-31 |
Supergen, Inc. |
Azacytosine analogs and derivatives
|
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
KR101498834B1
(ko)
|
2005-05-09 |
2015-03-05 |
오노 야꾸힝 고교 가부시키가이샤 |
예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
|
HRP20080053A2
(hr)
|
2005-07-01 |
2009-08-31 |
Medarex |
Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
US20070117776A1
(en)
|
2005-11-04 |
2007-05-24 |
John Lyons |
Low Dose Therapy Of DNA Methylation Inhibitors
|
|
US20070105792A1
(en)
|
2005-11-04 |
2007-05-10 |
Dimartino Jorge F |
Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
|
|
CN101637444B
(zh)
*
|
2006-03-17 |
2012-08-15 |
山东蓝金生物工程有限公司 |
含吉西他滨的抗癌药物缓释注射剂
|
|
EP2026805A1
(en)
*
|
2006-05-08 |
2009-02-25 |
Astex Therapeutics Limited |
Pharmaceutical combinations of diazole derivatives for cancer treatment
|
|
US8003324B2
(en)
*
|
2007-10-18 |
2011-08-23 |
U.S. Department Of Veterans Affairs |
Modulation of sodium channels by nicotinamide adenine dinucleotide
|
|
CN101570553B
(zh)
*
|
2008-05-04 |
2012-03-28 |
上海医药工业研究院 |
一种2-脱氧-d-核糖的衍生物及其制备方法和用途
|
|
CN101361718B
(zh)
|
2008-09-26 |
2013-08-28 |
深圳万乐药业有限公司 |
稳定的地西他滨冻干制剂的制备方法
|
|
CN101787046B
(zh)
*
|
2010-02-11 |
2012-12-26 |
福建南方制药股份有限公司 |
地西他滨的中间体化合物的制备方法
|
|
GB201006096D0
(en)
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
|
MX349622B
(es)
|
2010-09-08 |
2017-08-07 |
Halozyme Inc |
Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
|
|
CN101966157B
(zh)
*
|
2010-10-14 |
2013-08-14 |
苏州特瑞药业有限公司 |
一种地西他滨缓释微球及其制备方法
|
|
KR20140029446A
(ko)
|
2011-04-15 |
2014-03-10 |
컴퓨젠 엘티디. |
면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
|
|
PL2750768T3
(pl)
*
|
2011-08-30 |
2019-05-31 |
Astex Pharmaceuticals Inc |
Formulacje pochodnej decytabiny
|
|
US9872873B2
(en)
|
2012-02-06 |
2018-01-23 |
Fresenius Kabi Oncology Limited |
Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
|
|
RU2708246C2
(ru)
|
2013-03-01 |
2019-12-05 |
Астекс Фармасьютикалз, Инк. |
Комбинации лекарственных средств
|
|
HK1254645A1
(zh)
|
2015-07-02 |
2019-07-26 |
Otsuka Pharmaceutical Co., Ltd. |
冻乾药物组合物
|
|
EP3661522A2
(en)
|
2017-08-03 |
2020-06-10 |
Otsuka Pharmaceutical Co., Ltd. |
Drug compound and purification methods thereof
|